Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 15/20 | 0.56 |
| ▸ | CDK2AP1 | O14519 | 7/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | PARP1 | P09874 | 1/20 | 0.54 |
| ▸ | PBK | Q96KB5 | 2/20 | 0.52 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29392153 | 1.00 | CHEK1 (0.56) | CHEK1CDK2AP1KDM4EALDH1A1PARP1 | |
| SCHEMBL13161898 | 0.84 | ALDH1A1 (0.61) | KDM4EALDH1A1CRBN | |
| SCHEMBL22720116 | 0.84 | ALDH1A1 (0.66) | KDM4EALDH1A1CRBN | |
| SCHEMBL5654175 | 0.83 | CHEK1 (0.60) | CHEK1CDK2AP1PARP1PBK | |
| SCHEMBL1278935 | 0.83 | NPC1 (0.69) | CHEK1CDK2AP1PARP1PBK | |
| SCHEMBL1674869 | 0.83 | NPC1 (0.69) | CHEK1CDK2AP1PARP1PBK | |
| SCHEMBL31227213 | 0.83 | CHEK1 (0.60) | CHEK1CDK2AP1PARP1PBK | |
| SCHEMBL1278937 | 0.83 | NPC1 (0.69) | CHEK1CDK2AP1PARP1PBK | |
| SCHEMBL11056410 | 0.82 | ALDH1A1 (0.56) | CHEK1KDM4EALDH1A1PARP1CRBN | |
| SCHEMBL2154833 | 0.82 | ALDH1A1 (0.69) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9045437-B2 | 2-aryl-4-quinazolinones and their pharmaceutical compositions | CHINA MEDICAL UNIVERSITY (TW) | 2015-06-02 | — | — | US | disclosed |
| US-9006239-B2 | 2-aryl-4-quinazolinones and their pharmaceutical compositions | CHINA MEDICAL UNIVERSITY (TW) | 2015-04-14 | — | — | US | disclosed |
| US-8710064-B2 | 2-aryl-4-quinazolinones and their pharmaceutical compositions | CHINA MEDICAL UNIVERSITY (TW) | 2014-04-29 | — | — | US | disclosed |
| US-20140018363-A1 | 2-ARYL-4-QUINAZOLINONES AND THEIR PHARMACEUTICAL COMPOSITIONS | CHINA MEDICAL UNIVERSITY (TW) | 2014-01-16 | — | — | US | disclosed |
| US-20130310376-A1 | 2-ARYL-4-QUINAZOLINONES AND THEIR PHARMACEUTICAL COMPOSITIONS | CHINA MEDICAL UNIVERSITY (TW) | 2013-11-21 | — | — | US | disclosed |
| US-20130102602-A1 | 2-Aryl-4-Quinazolinones And Their Pharmaceutical Compositions | CHINA MEDICAL UNIVERSITY (TW) | 2013-04-25 | — | — | US | disclosed |
| US-6479499-B1 | INHIBITORS OF TUBULIN POLYMERIZATION | NATIONAL SCIENCE COUNCIL (TW) | 2002-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102602-A1 | 2-Aryl-4-Quinazolinones And Their Pharmaceutical Compositions | AQP4, KRAS, RB1 | CHEK1 2769/4885CDK2AP1 2649/4885KDM4E 1135/4885 |
| US-20130310376-A1 | 2-ARYL-4-QUINAZOLINONES AND THEIR PHARMACEUTICAL COMPOSITIONS | CCNE2, NFE2, NR2E1 | CHEK1 3278/4885CDK2AP1 2157/4885KDM4E 51/4885 |
| US-20140018363-A1 | 2-ARYL-4-QUINAZOLINONES AND THEIR PHARMACEUTICAL COMPOSITIONS | CCNE2, RB1, NR2E1 | CHEK1 3212/4885CDK2AP1 2207/4885KDM4E 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.